JP2024020436A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024020436A5 JP2024020436A5 JP2023195187A JP2023195187A JP2024020436A5 JP 2024020436 A5 JP2024020436 A5 JP 2024020436A5 JP 2023195187 A JP2023195187 A JP 2023195187A JP 2023195187 A JP2023195187 A JP 2023195187A JP 2024020436 A5 JP2024020436 A5 JP 2024020436A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- amino acid
- acid sequence
- scfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020198044 | 2020-11-30 | ||
| JP2020198044 | 2020-11-30 | ||
| JP2021110912 | 2021-07-02 | ||
| JP2021110912 | 2021-07-02 | ||
| PCT/JP2021/043538 WO2022114163A1 (ja) | 2020-11-30 | 2021-11-29 | Ｈｅｒ２標的化剤 |
| JP2022565479A JP7393774B2 (ja) | 2020-11-30 | 2021-11-29 | Ｈｅｒ２標的化剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565479A Division JP7393774B2 (ja) | 2020-11-30 | 2021-11-29 | Ｈｅｒ２標的化剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024020436A JP2024020436A (ja) | 2024-02-14 |
| JP2024020436A5 true JP2024020436A5 (enExample) | 2024-12-16 |
Family
ID=81754499
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565479A Active JP7393774B2 (ja) | 2020-11-30 | 2021-11-29 | Ｈｅｒ２標的化剤 |
| JP2023195187A Pending JP2024020436A (ja) | 2020-11-30 | 2023-11-16 | Ｈｅｒ２標的化剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565479A Active JP7393774B2 (ja) | 2020-11-30 | 2021-11-29 | Ｈｅｒ２標的化剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240002531A1 (enExample) |
| EP (1) | EP4253420A4 (enExample) |
| JP (2) | JP7393774B2 (enExample) |
| KR (1) | KR20230114747A (enExample) |
| AU (1) | AU2021387127A1 (enExample) |
| CA (1) | CA3199473A1 (enExample) |
| IL (1) | IL303154A (enExample) |
| MX (1) | MX2023005864A (enExample) |
| TW (2) | TW202229359A (enExample) |
| WO (1) | WO2022114163A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4253420A4 (en) * | 2020-11-30 | 2024-11-06 | ONO Pharmaceutical Co., Ltd. | HER2 TARGETING AGENT |
| KR20250005097A (ko) * | 2022-04-08 | 2025-01-09 | 페이트 세러퓨틱스, 인코포레이티드 | 고형 종양 표적화 골격을 갖는 세포 및 이의 용도 |
| KR20250004622A (ko) | 2022-04-08 | 2025-01-08 | 페이트 세러퓨틱스, 인코포레이티드 | 종양 표적화를 위한 키메라 항원 수용체 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| EP2330131B1 (en) | 2009-12-07 | 2014-10-08 | Fundació Privada Institució Catalana De Recerca I Estudis Avancats | Antibodies against HER2 truncated variant CTF-611 |
| US9243057B2 (en) * | 2010-08-31 | 2016-01-26 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
| US11851479B2 (en) * | 2018-06-18 | 2023-12-26 | Dxdiscovery, Inc. | Methods and compositions for pertussis diagnosis |
| EP4253420A4 (en) * | 2020-11-30 | 2024-11-06 | ONO Pharmaceutical Co., Ltd. | HER2 TARGETING AGENT |
| KR20250004622A (ko) * | 2022-04-08 | 2025-01-08 | 페이트 세러퓨틱스, 인코포레이티드 | 종양 표적화를 위한 키메라 항원 수용체 |
-
2021
- 2021-11-29 EP EP21898135.5A patent/EP4253420A4/en active Pending
- 2021-11-29 WO PCT/JP2021/043538 patent/WO2022114163A1/ja not_active Ceased
- 2021-11-29 US US18/038,185 patent/US20240002531A1/en active Pending
- 2021-11-29 TW TW110144472A patent/TW202229359A/zh unknown
- 2021-11-29 CA CA3199473A patent/CA3199473A1/en active Pending
- 2021-11-29 JP JP2022565479A patent/JP7393774B2/ja active Active
- 2021-11-29 IL IL303154A patent/IL303154A/en unknown
- 2021-11-29 KR KR1020237017469A patent/KR20230114747A/ko active Pending
- 2021-11-29 TW TW114129312A patent/TW202546008A/zh unknown
- 2021-11-29 MX MX2023005864A patent/MX2023005864A/es unknown
- 2021-11-29 AU AU2021387127A patent/AU2021387127A1/en active Pending
-
2023
- 2023-08-04 US US18/365,828 patent/US11981747B1/en active Active
- 2023-11-16 JP JP2023195187A patent/JP2024020436A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022101693A5 (enExample) | ||
| JP2023543031A5 (enExample) | ||
| JP2021534096A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| JP2013502913A5 (enExample) | ||
| JP2023529842A5 (enExample) | ||
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JP2026041845A5 (enExample) | ||
| JP2025069432A5 (enExample) | ||
| JP2007515165A5 (enExample) | ||
| JP2025507817A5 (enExample) | ||
| JP2023543493A5 (enExample) | ||
| JP2024504390A5 (enExample) | ||
| JP2023536461A5 (enExample) | ||
| JP2024538669A5 (enExample) | ||
| JP2020522488A5 (enExample) | ||
| IL276675B2 (en) | Anti-PD-1 antibodies and uses thereof | |
| JP2024536881A5 (enExample) | ||
| Yang et al. | A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues | |
| JP2023516941A5 (enExample) | ||
| JP2025503229A5 (enExample) | ||
| JP2024512574A5 (enExample) | ||
| JP2025508867A5 (enExample) | ||
| JP2023517794A5 (enExample) | ||
| JP2025513745A5 (enExample) |